Myomaker Bio has secured £325,000 in investment from SFC Capital to accelerate the development
of its lab-grown human muscle technology.
The company, a spin-out from Loughborough University, is pioneering the use of engineered human
muscle tissues to transform how new medicines are tested.
By creating functional muscle models that replicate the structure and behaviour of human tissue,
the company enables researchers to generate more predictive human data earlier in the drug
development process.
Now based in new laboratory facilities in Holborn, London, the company will use the new funding to
expand its scientific team, scale production of its muscle models and accelerate commercial
partnerships.
Professor Mark Lewis, Myomaker Bio’s CEO, said: “It is extremely satisfying to see this outcome
after many years of work in this area alongside our incredible team. For our investors to believe in us
and our technologies is humbling and gratifying.
“Drug development remains slow, expensive and heavily dependent on animal models that don’t
always predict human outcomes. Our human muscle platforms are designed to bridge that gap.
“This investment allows us to scale our technology to bring safer, more effective treatments to
patients faster.”
Adam Beveridge, Principal at SFC Capital, said: “The work that Myomaker Bio is doing is at the
cutting edge of biology and technology development, and we’re proud to be able to support this
exciting spinout business with £325k of pre-seed funding.”
The technology builds on more than 50 years of combined research by the founding team, who have
secured over £37 million in R&D funding and published more than 100 peer-reviewed papers in the
field of muscle biology.
Professor Dan Parsons, Loughborough University’s Pro Vice-Chancellor for Research and Innovation,
said: “This is an exciting moment for Myomaker Bio and for Loughborough University’s innovation
ecosystem. The team’s pioneering work in engineered human muscle systems is opening entirely
new possibilities for safer, faster and more human-relevant drug discovery. This investment will
accelerate their journey from breakthrough science to real-world impact, and we are delighted to see
Myomaker Bio take this significant next step.”